Cargando…
Evaluation of Blood Tumor Mutation Burden for the Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial
This study aimed to investigate the feasibility of blood-based biomarkers, including blood tumor mutation burden (bTMB), to predict atezolizumab efficacy in relapsed and advanced non-small cell lung cancer (NSCLC). Stage IV NSCLC patients who had previously received platinum-doublet chemotherapy wer...
Autores principales: | Park, Cheol-Kyu, Jun, Ha Ra, Oh, Hyung-Joo, Lee, Ji-Young, Cho, Hyun-Ju, Kim, Young-Chul, Lee, Jeong Eun, Yoon, Seong Hoon, Choi, Chang Min, Lee, Jae Cheol, Lee, Sung Yong, Lee, Shin Yup, Chun, Sung-Min, Oh, In-Jae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177441/ https://www.ncbi.nlm.nih.gov/pubmed/37174645 http://dx.doi.org/10.3390/cells12091246 |
Ejemplares similares
-
Phase II open‐label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid‐Lung‐A
por: Park, Cheol‐Kyu, et al.
Publicado: (2020) -
Buddy Taping: Is It a Safe Method for Treatment of Finger and Toe Injuries?
por: Won, Sung Hun, et al.
Publicado: (2014) -
Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial
por: Park, Cheol-Kyu, et al.
Publicado: (2022) -
Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer
por: Park, Cheol-Kyu, et al.
Publicado: (2021) -
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)